OverviewSuggest Edit

RenovoRx is a clinical-stage biopharmaceutical company focused on developing therapies for the local treatment of solid tumors. It offers a therapy platform, RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) that combines the RenovoCath delivery system with small molecule chemotherapeutic agents that can be forced across the vessel wall using pressure, targeting anti-cancer drugs locally to the solid tumors. The company also develops RenovoGem, a drug and device combination consisting of intra-arterial gemcitabine and RenovoCath.
TypePublic
Founded2012
HQLos Altos, CA, US
Websiterenovorx.com

Latest Updates

Employees (est.) (Jul 2021)7
Share Price (Oct 2021)$5.9(-2%)
Cybersecurity ratingAMore
Discover new suppliers and conduct deeper comparison analysis with Craft for EnterpriseLearn more
Banner background

Key People/Management at RenovoRx

Shaun R. Bagai

Shaun R. Bagai

Chief Executive Officer
Ramtin Agah

Ramtin Agah

Chairman of Board, Chief Medical Officer and Founder
Joe Paraschac

Joe Paraschac

Vice President of Operations
Nicole Lama

Nicole Lama

Director of Clinical Operations and Research
Angela MacFarlane

Angela MacFarlane

Director
David Diamond

David Diamond

Director
Show more

RenovoRx Office Locations

RenovoRx has an office in Los Altos
Los Altos, CA, US (HQ)
4546 El Camino Real, Suite B1
Show all (1)

RenovoRx Financials and Metrics

RenovoRx Revenue

Market capitalization (27-Sept-2021)

53.1m

Closing stock price (27-Sept-2021)

7.0
RenovoRx's current market capitalization is $53.1 m.
Show all financial metrics

RenovoRx Cybersecurity Score

Cybersecurity ratingPremium dataset

A

95/100

SecurityScorecard logo

RenovoRx Online and Social Media Presence

Embed Graph

RenovoRx News and Updates

RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors

LOS ALTOS, Calif., Sept. 7, 2021 /PRNewswire/ -- RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its proprietary RenovoCath...

RenovoRx Announces Pricing of Initial Public Offering

LOS ALTOS, Calif., Aug. 25, 2021 /PRNewswire/ -- RenovoRx, Inc., a biopharmaceutical company and innovator in targeted cancer therapy, today announced the pricing of its underwritten initial public offering of 1,850,000 units at a public offering price per unit of $9.00. Each unit...

RenovoRx Announces Issuance of Seventh U.S. Patent

LOS ALTOS, Calif., July 8, 2021 /PRNewswire/ -- RenovoRx, a biopharmaceutical company and innovator in targeted cancer therapy, today announced the United States Patent and Trademark Office issued U.S. Patent No. 11,052,224. This new patent extends the Company's extensive coverage of its...

RenovoRx Blogs

RenovoRx Receives New 510(k) Clearance for its RenovoCath® Delivery System Designed for Targeted Treatment of Solid Tumors

510(k) Device May Improve Targeted Delivery of Chemotherapy Los Altos, CA, September 7, 2021 – RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced it has received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) …

Doctors Testing ‘Groundbreaking’ Treatment for Pancreatic Cancer

CHARLOTTE, N.C. — A new treatment for pancreatic cancer is being tested out in clinical trials in several states, and one North Carolina doctor called it “groundbreaking.” The trials are being conducted in multiple cities across the country, including in North Carolina, California, New York, Florida…

Lakewood Ranch Pancreatic Cancer Patient Receives New Treatment

A Lakewood Ranch retiree is one of the first patients in the country to receive an experimental treatment for pancreatic cancer through a trial offered at Sarasota Memorial Hospital. Vince Scully, 74, was diagnosed with Stage III pancreatic cancer in June, and initially underwent the standard treatm…

RenovoRx Announces Studies that Further Advance the Science of Pancreatic Cancer Treatment Presented at the 2021 ASCO Gastrointestinal Cancers Symposium

Conference was Held January 15-17, 2021 Los Altos, CA, January 20, 2021 – RenovoRx, an innovator in targeted cancer therapy, today announced two research studies were presented at the 2021 ASCO Gastrointestinal Cancers Symposium that further advance the science of pancreatic cancer treatment. In one…

RenovoRx Continues with Strong Momentum and Reaches Milestone of 100th Patient Enrolled in its Phase III TIGeR-PaC Clinical Trial

During this Unprecedented Time with the COVID-19 Pandemic, Patients Continue to Elect Participation in this Important Trial Los Altos, CA, December 2, 2020 – RenovoRx, an innovator in targeted cancer therapy, today announced it has reached an important milestone with continued momentum and the enrol…

RenovoRx Frequently Asked Questions

  • When was RenovoRx founded?

    RenovoRx was founded in 2012.

  • Who are RenovoRx key executives?

    RenovoRx's key executives are Shaun R. Bagai, Ramtin Agah and Joe Paraschac.

  • How many employees does RenovoRx have?

    RenovoRx has 7 employees.

  • Who are RenovoRx competitors?

    Competitors of RenovoRx include SynCore Biotechnology, NovoCure and TriSalus Life Sciences.

  • Where is RenovoRx headquarters?

    RenovoRx headquarters is located at 4546 El Camino Real, Suite B1, Los Altos.

  • Where are RenovoRx offices?

    RenovoRx has an office in Los Altos.

  • How many offices does RenovoRx have?

    RenovoRx has 1 office.